Want to see MCK full AI Analyst Report?
MCK Stock Chart & Stats
$760.57
$1.72(0.29%)
At close: 4:00 PM EST
$760.57
$1.72(0.29%)
Day’s Range― - ―
52-Week Range$637.00 - $999.00
Previous CloseN/A
Volume137.88K
Average Volume (3M)1.11M
Market Cap
$92.82B
Enterprise Value$98.37B
Total Cash (Recent Filing)$3.98B
Total Debt (Recent Filing)$8.61B
Price to Earnings (P/E)20.8
Beta0.19
Next Earnings
Aug 05, 2026EPS Estimate
9.61Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)38.64
Shares Outstanding117,077,740
10 Day Avg. Volume1,137,178
30 Day Avg. Volume1,110,177
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)-49.24
Price to Sales (P/S)0.27
P/FCF Ratio18.70
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue0.24
Enterprise Value/Gross Profit6.76
Enterprise Value/Ebitda14.02
Forecast
1Y Price Target
$935.55Price Target Upside23.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)44.24
Revenue Forecast (FY)$432.45B
Bulls Say, Bears Say
Bulls Say
Scale & Revenue RecoveryMcKesson’s massive distribution scale and recent revenue recovery to ~$403B with ~ $4.8B net income shows durable market position. Large volumes across pharmacies, health systems and specialty channels create purchasing leverage and recurring cash flows that support resilience versus smaller competitors.
Strong Cash Generation & Capital ReturnsConsistent operating cash flow and meaningful free cash flow enabled sizable buybacks and dividends, reflecting durable cash conversion in distribution. This cash generation supports strategic investments, deleveraging or shareholder returns over multiple years, increasing financial flexibility despite working-capital swings.
Oncology & Specialty Scale And ContributionsRapid oncology and multispecialty expansion increases exposure to higher-value, service-rich workflows. Provider additions and targeted acquisitions deepen clinical services and specialty distribution capabilities, creating stickier customer relationships and higher-margin revenue streams that should persist with aging populations and complex therapies.
Bears Say
Structurally Thin MarginsMcKesson operates a high-volume, low-margin distribution model where small pricing or mix shifts materially affect profits. Structural gross and net margins under 4% and ~1% respectively limit margin expansion potential and make earnings highly sensitive to branded pricing, reimbursement changes, and purchasing terms.
Balance-sheet History And Leverage RelianceAlthough equity is positive now, the recent multi-year negative equity episode raises structural risk and investor sensitivity to shocks. Meaningful reliance on debt (debt/equity ~1.25x) can constrain flexibility, increase funding cost sensitivity, and amplify equity volatility during economic or execution stress.
Cash-flow Volatility & Higher Interest From SeparationSharp year-over-year FCF swings highlight working-capital and normalization risk typical in distribution. Planned separation financing raises interest costs and guides lower FCF, reducing margin for error on investments and buybacks and increasing sensitivity to operational hiccups or regulatory delays tied to the Medical‑Surgical separation.
McKesson News
MCK FAQ
What was McKesson Corporation’s price range in the past 12 months?
McKesson Corporation lowest stock price was $637.00 and its highest was $999.00 in the past 12 months.
What is McKesson Corporation’s market cap?
McKesson Corporation’s market cap is $92.82B.
When is McKesson Corporation’s upcoming earnings report date?
McKesson Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 25 days.
How were McKesson Corporation’s earnings last quarter?
McKesson Corporation released its earnings results on May 07, 2026. The company reported $11.69 earnings per share for the quarter, beating the consensus estimate of $11.565 by $0.125.
Is McKesson Corporation overvalued?
According to Wall Street analysts McKesson Corporation’s price is currently Undervalued.
Does McKesson Corporation pay dividends?
McKesson Corporation pays a Quarterly dividend of $0.82 which represents an annual dividend yield of 0.37%. See more information on McKesson Corporation dividends here
What is McKesson Corporation’s EPS estimate?
McKesson Corporation’s EPS estimate is 9.61.
How many shares outstanding does McKesson Corporation have?
McKesson Corporation has 117,077,740 shares outstanding.
What happened to McKesson Corporation’s price movement after its last earnings report?
McKesson Corporation reported an EPS of $11.69 in its last earnings report, beating expectations of $11.565. Following the earnings report the stock price went down -2.474%.
Which hedge fund is a major shareholder of McKesson Corporation?
Currently, no hedge funds are holding shares in MCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$935.55 (23.01% Upside)
$935.55 (23.01% Upside)
Blogger Sentiment
Bullish
MCK Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 323.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.25%
12-Months-Change
Fundamentals
Return on Equity
-265.44%
Trailing 12-Months
Asset Growth
9.56%
Trailing 12-Months
Company Description
McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
MCK Company Deck
MCK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
McKesson reported a strong fiscal 2026 with double-digit revenue, operating profit and EPS growth, robust cash generation and material progress on strategic initiatives (oncology expansion, biopharma scale, supply chain modernization, and Medical‑Surgical separation). The company is returning significant capital to shareholders and reaffirmed long‑term targets. Offsetting risks include branded pricing pressure (IRA effects), sequential GLP‑1 volatility, ongoing integration and corporate expense investments, and near‑term cash flow/interest impacts related to separation financing. On balance the positives (broad-based growth, margin expansion, cash returns, strategic progress) outweigh the negatives, though the business faces near-term variability and execution/approval risks tied to the Medical‑Surgical separation.View all MCK earnings summariesMCK Revenue Breakdown
83.45% North American Pharmaceutical
12.00% Oncology & Multispecialty
1.44% Prescription Technology Solutions
2.85% Medical-Surgical Solutions
0.26% Other
MCK Stock 12 Month Forecast
Average Price Target
$935.55
▲(23.01% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
24.04% Mutual Funds
0.41% Other Institutional Investors
51.88% Public Companies and Individual Investors